Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Yang, Xiao Feng ^a   Jan, Michael ^a   Meng, Shu ^a   Chen, Natalie C ^a   Mai, Jietang ^a   Wang, Hong ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD40 LIGAND; FRACTALKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; PHOSPHATIDYLCHOLINE; PNEUMOCOCCUS VACCINE; VASCULAR CELL ADHESION MOLECULE 1; VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ATHEROSCLEROSIS; BIOINFORMATICS; CD4+ T LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; ENDOTHELIUM CELL; EPITOPE MAPPING; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MONOCYTE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; T LYMPHOCYTE ACTIVATION; ANIMAL; AUTOIMMUNITY; BIOLOGY; CHEMISTRY; INFLAMMATION; METHODOLOGY;

ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNITY; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HUMANS; INFLAMMATION; VACCINES;

EID: 77952466815     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/459798     Document Type: Review

References (181)

1. Hansson G. K., Libby P., The immune response in atherosclerosis: a double-edged sword Nature Reviews Immunology 2006 6 7 508 519
2. Jonasson L., Holm J., Skalli O., Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque Arteriosclerosis 1986 6 2 131 138
3. Jonasson L., Holm J., Skalli O., Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis Journal of Clinical Investigation 1985 76 1 125 131
4. Kovanen P. T., Kaartinen M., Paavonen T., Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction Circulation 1995 92 5 1084 1088
5. Caligiuri G., Rudling M., Ollivier V., Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice Molecular Medicine 2003 9 1-2 10 17
6. Mallat Z., Gojova A., Marchiol-Fournigault C., Inhibition of transforming growth factor-signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice Circulation Research 2001 89 10 930 934
7. Rocha V. Z., Libby P., Obesity, inflammation, and atherosclerosis Nature Reviews 2009 6 6 399 409
8. Tedgui A., Mallat Z., Cytokines in atherosclerosis: pathogenic and regulatory pathways Physiological Reviews 2006 86 2 515 581
9. Binder C. J., Hartvigsen K., Chang M.-K., IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis Journal of Clinical Investigation 2004 114 3 427 437
10. Buono C., Binder C. J., Stavrakis G., Witztum J. L., Glimcher L. H., Lichtman A. H., T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses Proceedings of the National Academy of Sciences of the United States of America 2005 102 5 1596 1601
11. Laurat E., Poirier B., Tupin E., In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice Circulation 2001 104 2 197 202
12. Nilsson J., Hansson G. K., Autoimmunity in atherosclerosis: a protective response losing control? Journal of Internal Medicine 2008 263 5 464 478
13. Berenson G. S., Srinivasan S. R., Bao W., Newman W. P. III, Tracy R. E., Wattigney W. A., Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults The New England Journal of Medicine 1998 338 23 1650 1656
14. Tegos T. J., Kalodiki E., Sabetai M. M., Nicolaides A. N., The genesis of atherosclerosis and risk factors: a review Angiology 2001 52 2 89 98
15. Maron B. A., Loscalzo J., The treatment of hyperhomocysteinemia Annual Review of Medicine 2009 60 39 54
16. Wang H., Jiang X., Yang F., Hyperhomocysteinemia accelerates atherosclerosis in cystathionine-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation Blood 2003 101 10 3901 3907
17. Zhang D., Jiang X., Fang P., Hyperhomocysteinemia promotes inflammatory monocyte generation and accelerates atherosclerosis in transgenic cystathionine-synthase-deficient mice Circulation 2009 120 19 1893 1902
18. Campbell L. A., Kuo C.-C., Chlamydia pneumoniaean infectious risk factor for atherosclerosis? Nature Reviews Microbiology 2004 2 1 23 32
19. Cybulsky M. I., Iiyama K., Li H., A major role for VCAM-1, but not ICAM-1, in early atherosclerosis Journal of Clinical Investigation 2001 107 10 1255 1262
20. Collins R. G., Velji R., Guevara N. V., Hicks M. J., Chan L., Beaudet A. L., P-selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice Journal of Experimental Medicine 2000 191 1 189 194
21. Dong Z. M., Chapman S. M., Brown A. A., Frenette P. S., Hynes R. O., Wagner D. D., The combined role of P-and E-selectins in atherosclerosis Journal of Clinical Investigation 1998 102 1 145 152
22. Cushing S. D., Berliner J. A., Valente A. J., Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells Proceedings of the National Academy of Sciences of the United States of America 1990 87 13 5134 5138
23. Subbanagounder G., Wong J. W., Lee H., Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1 The Journal of Biological Chemistry 2002 277 9 7271 7281
24. Boring L., Gosling J., Cleary M., Charo I. F., Decreased lesion formation in CCR 2-/-mice reveals a role for chemokines in the initiation of atherosclerosis Nature 1998 394 6696 894 897
25. Gosling J., Slaymaker S., Gu L., MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B Journal of Clinical Investigation 1999 103 6 773 778
26. Gu L., Okada Y., Clinton S. K., Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice Molecular Cell 1998 2 2 275 281
27. Combadiere C., Potteaux S., Gao J.-L., Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice Circulation 2003 107 7 1009 1016
28. Yang X.-F., Yin Y., Wang H., Vascular inflammation and atherogenesis are activated via receptors for PAMPs and suppressed by regulatory T cells Drug Discovery Today: Therapeutic Strategies 2008 5 2 125 142
29. Edfeldt K., Swedenborg J., Hansson G. K., Yan Z.-Q., Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation Circulation 2002 105 10 1158 1161
30. Michelsen K. S., Wong M. H., Shah P. K., Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E Proceedings of the National Academy of Sciences of the United States of America 2004 101 29 10679 10684
31. Kol A., Lichtman A. H., Finberg R. W., Libby P., Kurt-Jones E. A., Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells Journal of Immunology 2000 164 1 13 17
32. Xu X. H., Shah P. K., Faure E., Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL Circulation 2001 104 25 3103 3108
33. Yin Y., Yan Y., Jiang X., Inflammasomes are differentially expressed in cardiovascular and other tissues International Journal of Immunopathology and Pharmacology 2009 22 2 311 322
34. Eisenbarth S. C., Colegio O. R., OConnor W. Jr., Sutterwala F. S., Flavell R. A., Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants Nature 2008 453 7198 1122 1126
35. Li H., Willingham S. B., Ting J. P.-Y., Re F., Cutting edge: inflammasome activation by alum and alums adjuvant effect are mediated by NLRP3 Journal of Immunology 2008 181 1 17 21
36. Demento S. L., Eisenbarth S. C., Foellmer H. G., Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy Vaccine 2009 27 23 3013 3021
37. Peiser L., Mukhopadhyay S., Gordon S., Scavenger receptors in innate immunity Current Opinion in Immunology 2002 14 1 123 128
38. Nicoletti A., Caligiuri G., Tornberg I., Kodama T., Stemme S., Hansson G. K., The macrophage scavenger receptor type A directs modified proteins to antigen presentation European Journal of Immunology 1999 29 2 512 521
39. Glass C. K., Witztum J. L., Atherosclerosis: the road ahead Cell 2001 104 4 503 516
40. Krieger M., Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems Journal of Clinical Investigation 2001 108 6 793 797
41. Febbraio M., Hajjar D. P., Silverstein R. L., CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism Journal of Clinical Investigation 2001 108 6 785 791
42. Choi J.-H., Do Y., Cheong C., Identification of antigen-presenting dendritic cells in mouse aorta and cardiac valves Journal of Experimental Medicine 2009 206 3 497 505
43. Mach F., Schonbeck U., Sukhova G. K., Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis Proceedings of the National Academy of Sciences of the United States of America 1997 94 5 1931 1936
44. Mach F., Schonbeck U., Sukhova G. K., Atkinson E., Libby P., Reduction of atherosclerosis in mice by inhibition of CD40 signalling Nature 1998 394 6689 200 203
45. Lutgens E., Cleutjens K. B. J. M., Heeneman S., Koteliansky V. E., Burkly L. C., Daemen M. J. A. P., Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype Proceedings of the National Academy of Sciences of the United States of America 2000 97 13 7464 7469
46. Janeway C. A. T., Walport M., Shlomchik M. J., Immunobiology 2005 6th New York, NY, USA Garland Science Publishing
47. Binder C. J., Chang M.-K., Shaw P. X., Innate and acquired immunity in atherogenesis Nature Medicine 2002 8 11 1218 1226
48. Veldhoen M., Uyttenhove C., van Snick J., Transforming growth factor-reprograms the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset Nature Immunology 2008 9 12 1341 1346
49. Weaver C. T., Hatton R. D., Interplay between the TH 17 and TReg cell lineages: a (co-)evolutionary perspective Nature Reviews Immunology 2009 9 12 883 889
50. King C., New insights into the differentiation and function of T follicular helper cells Nature Reviews Immunology 2009 9 11 757 766
51. Dansky H. M., Charlton S. A., Harper M. M., Smith J. D., T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse Proceedings of the National Academy of Sciences of the United States of America 1997 94 9 4642 4646
52. Daugherty A., Pure E., Delfel-Butteiger D., The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/-mice Journal of Clinical Investigation 1997 100 6 1575 1580
53. Reardon C. A., Blachowicz L., White T., Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 6 1011 1016
54. Song L., Leung C., Schindler C., Lymphocytes are important in early atherosclerosis Journal of Clinical Investigation 2001 108 2 251 259
55. + T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice Circulation 2000 102 24 2919 2922
56. Frostegard J., Ulfgren A.-K., Nyberg P., Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines Atherosclerosis 1999 145 1 33 43
57. Stemme S., Faber B., Holm J., Wiklund O., Witztum J. L., Hansson G. K., T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein Proceedings of the National Academy of Sciences of the United States of America 1995 92 9 3893 3897
58. Uyemura K., Demer L. L., Castle S. C., Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis Journal of Clinical Investigation 1996 97 9 2130 2138
59. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S., Inhibition of tumor necrosis factor-reduces atherosclerosis in apolipoprotein E knockout mice Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 11 2137 2142
60. Buono C., Come C. E., Stavrakis G., Maguire G. F., Connelly P. W., Lichtman A. H., Influence of interferon-on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 3 454 460
61. Davenport P., Tipping P. G., The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice American Journal of Pathology 2003 163 3 1117 1125
62. Elhage R., Jawien J., Rudling M., Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice Cardiovascular Research 2003 59 1 234 240
63. Gupta S., Pablo A. M., Jiang X.-C., Wang N., Tall A. R., Schindler C., IFN-, potentiates atherosclerosis in ApoE knock-out mice Journal of Clinical Investigation 1997 99 11 2752 2761
64. Whitman S. C., Ravisankar P., Elam H., Daugherty A., Exogenous interferon-enhances atherosclerosis in apolipoprotein E-/-mice American Journal of Pathology 2000 157 6 1819 1824
65. Huber S. A., Sakkinen P., David C., Newell M. K., Tracy R. P., T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia Circulation 2001 103 21 2610 2616
66. Paigen B., Morrow A., Brandon C., Variation in susceptibility to atherosclerosis among inbred strains of mice Atherosclerosis 1985 57 1 65 73
67. Pinderski L. J., Fischbein M. P., Subbanagounder G., Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes Circulation Research 2002 90 10 1064 1071
68. King V. L., Szilvassy S. J., Daugherty A., Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/-mice Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 3 456 461
69. Friesel R., Komoriya A., Maciag T., Inhibition of endothelial cell proliferation by-interferon Journal of Cell Biology 1987 104 3 689 696
70. Hansson G. K., Hellstrand M., Rymo L., Rubbia L., Gabbiani G., Interferon inhibits both proliferation and expression of differentiation-specific-smooth muscle actin in arterial smooth muscle cells Journal of Experimental Medicine 1989 170 5 1595 1608
71. Lee E., Vaughan D. E., Parikh S. H., Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells Circulation Research 1996 78 1 44 49
72. Sarn P., Welgus H. G., Kovanen P. T., TNF-α and IL-1 selectively induce expression of 92-kDa gelatinase by human macrophages Journal of Immunology 1996 157 9 4159 4165
73. van Hinsbergh V. W. M., van den Berg E. A., Fiers W., Dooijewaard G., Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells Blood 1990 75 10 1991 1998
74. Andersson J., Libby P., Hansson G. K., Adaptive immunity and atherosclerosis Clinical Immunology 2010 134 1 33 46
75. Eid R. E., Rao D. A., Zhou J., Interleukin-17 and interferon-are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells Circulation 2009 119 10 1424 1432
76. Taleb S., Romain M., Ramkhelawon B., Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis Journal of Experimental Medicine 2009 206 10 2067 2077
77. Xie J.-J., Wang J., Tang T.-T., The Th17/Treg functional imbalance during atherogenesis in Apo E-/-mice Cytokine 2010 49 2 185 193
78. von Herrath M. G., Harrison L. C., Antigen-induced regulatory T cells in autoimmunity Nature Reviews Immunology 2003 3 3 223 232
79. + regulatory T cells International Journal of Immunopathology and Pharmacology 2007 20 1 75 89
80. Mallat Z., Ait-Oufella H., Tedgui A., Regulatory T-cell immunity in atherosclerosis Trends in Cardiovascular Medicine 2007 17 4 113 118
81. Xiong Z., Song J., Yan Y., Higher expression of Bax in regulatory T cells increases vascular inflammation Frontiers in Bioscience 2008 13 7143 7155
82. Xiong Z., Yan Y., Song J., Expression of TCTP antisense in CD25 high regulatory T cells aggravates cuff-injured vascular inflammation Atherosclerosis 2009 203 2 401 408
83. Riley J. L., June C. H., The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation Blood 2005 105 1 13 21
84. Beyersdorf N., Gaupp S., Balbach K., Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis Journal of Experimental Medicine 2005 202 3 445 455
85. Lin T., Hu J., Wang D., Stocco D. M., Interferon-inhibits the steroidogenic acute regulatory protein messenger ribonucleic acid expression and protein levels in primary cultures of rat Leydig cells Endocrinology 1998 139 5 2217 2222 (Pubitemid 28513739)
86. Suntharalingam G., Perry M. R., Ward S., Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 The New England Journal of Medicine 2006 355 10 1018 1028
87. Riley J. L., June C. H., Blazar B. R., Human T regulatory cell therapy: take a billion or so and call me in the morning Immunity 2009 30 5 656 665
88. de Boer O. J., van der Meer J. J., Teeling P., van der Loos C. M., van der Wal A. C., Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions PLoS ONE 2007 2 8, article e779
89. Caligiuri G., Nicoletti A., Poirierand B., Hansson G. K., Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice Journal of Clinical Investigation 2002 109 6 745 753
90. Major A. S., Fazio S., Linton M. F., B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice Arteriosclerosis, Thrombosis, and Vascular Biology 2002 22 11 1892 1898
91. Witztum J. L., Splenic immunity and atherosclerosis: a glimpse into a novel paradigm? Journal of Clinical Investigation 2002 109 6 721 724
92. van Leeuwen M., Damoiseaux J., Duijvestijn A., Tervaert J. W. C., The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis Autoimmunity Reviews 2009 9 1 53 57
93. Yanaba K., Bouaziz J.-D., Matsushita T., Magro C. M., St.Clair E. W., Tedder T. F., B-lymphocyte contributions to human autoimmune disease Immunological Reviews 2008 223 1 284 299
94. Binder C. J., Silverman G. J., Natural antibodies and the autoimmunity of atherosclerosis Springer Seminars in Immunopathology 2005 26 4 385 404
95. Shaw P. X., Horkko S., Tsimikas S., Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 8 1333 1339
96. de Boer O. J., van der Wal A. C., Houtkamp M. A., Ossewaarde J. M., Teeling P., Becker A. E., Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae Cardiovascular Research 2000 48 3 402 408
97. Palinski W., Rosenfeld M. E., Yla-Herttuala S., Low density lipoprotein undergoes oxidative modification in vivo Proceedings of the National Academy of Sciences of the United States of America 1989 86 4 1372 1376
98. Paulsson G., Zhou X., Tornquist E., Hansson G. K., Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 1 10 17
99. Witztum J. L., Steinberg D., Role of oxidized low density lipoprotein in atherogenesis Journal of Clinical Investigation 1991 88 6 1785 1792
100. Rader D. J., Daugherty A., Translating molecular discoveries into new therapies for atherosclerosis Nature 2008 451 7181 904 913
101. Skalen K., Gustafsson M., Knutsen Rydberg E., Subendothelial retention of atherogenic lipoproteins in early atherosclerosis Nature 2002 417 6890 750 754
102. Tabas I., Williams K. J., Boren J., Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 2007 116 16 1832 1844
103. Ait-Oufella H., Kinugawa K., Zoll J., Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice Circulation 2007 115 16 2168 2177
104. Angeli V., Llodra J., Rong J. X., Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization Immunity 2004 21 4 561 574
105. Weyand C. M., Goronzy J. J., Medium-and large-vessel vasculitis The New England Journal of Medicine 2003 349 2 160 169
106. Gupta M., Vavasis C., Frishman W. H., Heat shock proteins in cardiovascular disease: a new therapeutic target Cardiology in Review 2004 12 1 26 30
107. Riley E., Dasari V., Frishman W. H., Sperber K., Vaccines in development to prevent and treat atherosclerotic disease Cardiology in Review 2008 16 6 288 300
108. Veres A., Fust G., Smieja M., Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events Circulation 2002 106 22 2775 2780
109. Bachmaier K., Penninger J. M., Chlamydia and antigenic mimicry Current Topics in Microbiology and Immunology 2005 296 153 163
110. Niessner A., Sato K., Chaikof E. L., Colmegna I., Goronzy J. J., Weyand C. M., Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-Circulation 2006 114 23 2482 2489
111. Rappuoli R., Miller H. I., Falkow S., Medicine: the intangible value of vaccination Science 2002 297 5583 937 939
112. Bailey J. M., Tomar R., lipoprotein immunization and induced atherosclerosis in rabbits. 1. Cockerel-lipoproteins as antigens The Lancet 1965 5 2 203 214
113. de Carvalho J. F., Pereira R. M., Shoenfeld Y., Vaccination for atherosclerosis Clinical Reviews in Allergy and Immunology 2010 38 2-3 135 140
114. Ger S., Some data on the influence of cholesterol atherosclerosis by immunological means Revue de lAtherosclerose et des Arteriopathies Peripheriques 1967 9 1, supplement 1 194 198
115. Ger S., Gergely J., Jakab L., Inhibition of cholesterol atherosclerosis by immunisation with-lipoprotein The Lancet 1959 274 7088 6 7
116. Siegler P. E., Some immunological aspects of atherosclerosis Revue de lAtherosclerose et des Arteriopathies Peripheriques 1967 9 1, supplement 1 199
117. Ameli S., Hultgardh-Nilsson A., Regnstrm J., Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits Arteriosclerosis, Thrombosis, and Vascular Biology 1996 16 8 1074 1079
118. Palinski W., Miller E., Witztum J. L., Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis Proceedings of the National Academy of Sciences of the United States of America 1995 92 3 821 825
119. Freigang S., Horkko S., Miller E., Witztum J. L., Palinski W., Immunization of LDL receptor-deficient mice with homologous malondialdehyde- modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes Arteriosclerosis, Thrombosis, and Vascular Biology 1998 18 12 1972 1982
120. George J., Afek A., Gilburd B., Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis Atherosclerosis 1998 138 1 147 152
121. Zhou X., Caligiuri G., Hamsten A., Lefvert A. K., Hansson G. K., LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 1 108 114
122. Barkowski R. S., Frishman W. H., HDL metabolism and CETP inhibition Cardiology in Review 2008 16 3 154 162
123. Davidson M. H., Maki K., Umporowicz D., Wheeler A., Rittershaus C., Ryan U., The safety and immunogenicity of a CETP vaccine in healthy adults Atherosclerosis 2003 169 1 113 120
124. Frishman W. H., Barkowski R. S., Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: real hope or despair? American Journal of Medicine 2008 121 8 644 646
125. Chou M.-Y., Hartvigsen K., Hansen L. F., Oxidation-specific epitopes are important targets of innate immunity Journal of Internal Medicine 2008 263 5 479 488
126. Binder C. J., Horkko S., Dewan A., Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL Nature Medicine 2003 9 6 736 743
127. Caligiuri G., Khallou-Laschet J., Vandaele M., Phosphorylcholine- targeting immunization reduces atherosclerosis Journal of the American College of Cardiology 2007 50 6 540 546
128. Chyu K.-Y., Zhao X., Reyes O. S., Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E-/-mice Biochemical and Biophysical Research Communications 2005 338 4 1982 1989
129. Frederikson G. N., Andersson L., Soderberg I., Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression Autoimmunity 2005 38 2 171 179
130. Fredrikson G. N., Soderberg I., Lindholm M., Inhibition of atherosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 5 879 884
131. Schiopu A., Bengtsson J., Soderberg I., Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis Circulation 2004 110 14 2047 2052
132. Wick G., Schett G., Amberger A., Kleindienst R., Xu Q., Is atherosclerosis an immunologically mediated disease? Immunology Today 1995 16 1 27 33
133. Xu Q., Dietrich H., Steiner H. J., Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65 Arteriosclerosis and Thrombosis 1992 12 7 789 799
134. Hansson G. K., Holm J., Interferon-inhibits arterial stenosis after injury Circulation 1991 84 3 1266 1272
135. Lamb D. J., Ferns G. A. A., The magnitude of the immune response to heat shock protein-65 following BCG immunisation is associated with the extent of experimental atherosclerosis Atherosclerosis 2002 165 2 231 240
136. Harats D., Yacov N., Gilburd B., Shoenfeld Y., George J., Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions Journal of the American College of Cardiology 2002 40 7 1333 1338
137. Maron R., Sukhova G., Faria A.-M., Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice Circulation 2002 106 13 1708 1715
138. Pockley A. G., Georgiades A., Thulin T., De Faire U., Frostegard J., Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension Hypertension 2003 42 3 235 238
139. Danesh J., Antibiotics in the prevention of heart attacks The Lancet 2005 365 9457 365 367
140. Burnett M. S., Zhu J., Miller J. M., Epstein S. E., Effects of hepatitis A vaccination on atherogenesis in a murine model Journal of Viral Hepatitis 2003 10 6 433 436
141. Foulds J., Burke M., Steinberg M., Williams J. M., Ziedonis D. M., Advances in pharmacotherapy for tobacco dependence Expert Opinion on Emerging Drugs 2004 9 1 39 53
142. Nides M., Update on pharmacologic options for smoking cessation treatment American Journal of Medicine 2008 121 4, supplement S20 S31
143. Reade R., Michel J. B., Carelli C., Huang H., Baussant T., Corvol P., Immunization against angiotensin I in the spontaneously hypertensive rat Archives des Maladies du Coeur et des Vaisseaux 1989 82 7 1323 1328
144. Zorrilla E. P., Iwasaki S., Moss J. A., Vaccination against weight gain Proceedings of the National Academy of Sciences of the United States of America 2006 103 35 13226 13231
145. Koizumi Y., Kurita-Ochiai T., Oguchi S., Yamamoto M., Nasal immunization with Porphyromonas gingivalis outer membrane protein decreases P. gingivalis-induced atherosclerosis and inflammation in spontaneously hyperlipidemic mice Infection and Immunity 2008 76 7 2958 2965
146. Reed S. G., Bertholet S., Coler R. N., Friede M., New horizons in adjuvants for vaccine development Trends in Immunology 2009 30 1 23 32
147. Wack A., Rappuoli R., Vaccinology at the beginning of the 21st century Current Opinion in Immunology 2005 17 4 411 418
148. Petrovsky N., Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity Vaccine 2006 24 supplement 2 S2/26 S2/29
149. Clements C. J., Griffiths E., The global impact of vaccines containing aluminium adjuvants Vaccine 2002 20 supplement 3 S24 S33
150. Brewer J. M., Conacher M., Hunter C. A., Mohrs M., Brombacher F., Alexander J., Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling Journal of Immunology 1999 163 12 6448 6454
151. Kool M., Ptrilli V., de Smedt T., Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome Journal of Immunology 2008 181 6 3755 3759
152. Kool M., Soulli T., van Nimwegen M., Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells Journal of Experimental Medicine 2008 205 4 869 882
153. Seubert A., Monaci E., Pizza M., Ohagan D. T., Wack A., The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells Journal of Immunology 2008 180 8 5402 5412
154. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson L. A., The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism Infection and Immunity 2001 69 2 1151 1159
155. Wigren M., Bengtsson D., Duner P., Atheroprotective effects of alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells Circulation Research 2009 104 12 e62 e70
156. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A., Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges Vaccine 2003 21 supplement 2 S89 S95
157. van Puijvelde G. H. M., Hauer A. D., De Vos P., Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis Circulation 2006 114 18 1968 1976
158. Philbin V. J., Levy O., Developmental biology of the innate immune response: implications for neonatal and infant vaccine development Pediatric Research 2009 65 supplement 5 98R 105R
159. Nicoletti A., Paulsson G., Caligiuri G., Zhou X., Hansson G. K., Induction of neonatal tolerance to oxidized lipoprotein reduces atherosclerosis in ApoE knockout mice Molecular Medicine 2000 6 4 283 290
160. Xiong Z., Shaibani A., Li Y.-P., Alternative splicing factor ASF/SF2 is down regulated in inflamed muscle Journal of Clinical Pathology 2006 59 8 855 861
161. Yang F., Yang X. F., New concepts in tumor antigens: their significance in future immunotherapies for tumors Cellular Molecular Immunology 2005 2 5 331 341
162. Yan Y., Phan L., Yang F., A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L1 Journal of Immunology 2004 172 1 651 660
163. Yang F., Chen I. H., Xiong Z., Yan Y., Wang H., Yang X.-F., Model of stimulation-responsive splicing and strategies in identification of immunogenic isoforms of tumor antigens and autoantigens Clinical Immunology 2006 121 2 121 133
164. Greenbaum J. A., Andersen P. H., Blythe M., Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools Journal of Molecular Recognition 2007 20 2 75 82
165. Korber B., LaBute M., Yusim K., Immunoinformatics comes of age PLoS Computational Biology 2006 2 6, article e71
166. Sette A., Fikes J., Epitope-based vaccines: an update on epitope identification, vaccine design and delivery Current Opinion in Immunology 2003 15 4 461 470
167. Khan A. M., Miotto O., Heiny A. T., A systematic bioinformatics approach for selection of epitope-based vaccine targets Cellular Immunology 2006 244 2 141 147
168. Giuliani M. M., Adu-Bobie J., Comanducci M., A universal vaccine for serogroup B meningococcus Proceedings of the National Academy of Sciences of the United States of America 2006 103 29 10834 10839
169. Robinson H. L., Amara R. R., T cell vaccines for microbial infections Nature Medicine 2005 11 4, supplement S25 S32
170. Wilson C. C., McKinney D., Anders M., Development of a DNA vaccine designed to induce cytotoxic T lymphocyte responses to multiple conserved epitopes in HIV-1 Journal of Immunology 2003 171 10 5611 5623
171. Jameson B. A., Wolf H., The antigenic index: a novel algorithm for predicting antigenic determinants Computer Applications in the Biosciences 1988 4 1 181 186
172. Saha S., Raghava G. P. S., Prediction of continuous B-cell epitopes in an antigen using recurrent neural network Proteins: Structure, Function and Genetics 2006 65 1 40 48
173. Odorico M., Pellequer J.-L., BEPITOPE: predicting the location of continuous epitopes and patterns in proteins Journal of Molecular Recognition 2003 16 1 20 22
174. Rubinstein N. D., Mayrose I., Martz E., Pupko T., Epitopia: a web-server for predicting B-cell epitopes BMC Bioinformatics 2009 10 287
175. Ponomarenko J., Bui H.-H., Li W., ElliPro: a new structure-based tool for the prediction of antibody epitopes BMC Bioinformatics 2008 9 514
176. Ng B., Yang F., Huston D. P., Increased noncanonical splicing of autoantigen transcripts provides the structural basis for expression of untolerized epitopes Journal of Allergy and Clinical Immunology 2004 114 6 1463 1470
177. Brusic V., Bajic V. B., Petrovsky N., Computational methods for prediction of T-cell epitopesa framework for modelling, testing, and applications Methods 2004 34 4 436 443
178. Yang X.-F., Mirkovic D., Zhang S., Processing sites are different in the generation of HLA-A2.1-restricted, T cell reactive tumor antigen epitopes and viral epitopes International Journal of Immunopathology and Pharmacology 2006 19 4 853 870
179. Brusic V., Zeleznikow J., Computational binding assays of antigenic peptides Letters in Peptide Science 1999 6 5-6 313 324
180. Buus S., Description and prediction of peptide-MHC binding: the human MHC project Current Opinion in Immunology 1999 11 2 209 213
181. Bhasin M., Raghava G. P. S., Prediction of CTL epitopes using QM, SVM and ANN techniques Vaccine 2004 22 23-24 3195 3204